ClinicalTrials.gg
CompletedNCT05148000Updated May 29, 2026Results posted

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

A Phase 3 interventional study of QM1114-DP in Glabellar Frown Lines and Canthal Lines, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study to assess aesthetic improvement following treatment with QM1114-DP.

Read the detailed description

This was an open-label, single-center multi-center study to assess aesthetic improvement in the Glabellar and Lateral Canthal regions following treatment with QM1114-DP.

02

Conditions studied

  • Glabellar Frown Lines
  • Canthal Lines
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female 18 years or older
  • Moderate to severe bilaterally symmetrical LCL as assessed by the investigator
  • Moderate to severe GL at maximum frown as assessed by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment
  • Female who was pregnant, breast feeding or intended to conceive a child during the study.
  • Known allergy to or any component of the product
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    QM1114-DP

    QM1114-DP

    Biological: QM1114-DP

Interventions

06

What researchers measure

Primary outcomes

  1. Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines)

    The GAIS is a 7-point scale ranging from 1 to 7 where 1 = "very much improved", 2 = "much improved", 3 ="improved", 4 = "no change", 5 = "worse", 6 = "much worse" and 7 = "very much worse". Participants were asked "How would you rate the change in appearance of your glabellar lines (lines between your eyebrows) at maximum frown compared with immediately before the injection?". Participants were then instructed to select on rating that best describes the degree to which the appearance of their glabellar lines at maximum frown has changed relative to baseline. The participant could review the baseline photographs to aid in the assessment. Responder rate is defined as percentage of participants who responds at least "Improved" (i.e., improved, much improved and very much improved) on the GAIS at maximum frown.

    Time frame: Month 1

  2. Responders Rate Using the GAIS at Maximum Smile (Lateral Canthal Lines)

    The GAIS is a 7-point scale ranging from 1 to 7 where 1 = "very much improved", 2 = "much improved", 3 ="improved", 4 = "no change", 5 = "worse", 6 = "much worse" and 7 = "very much worse". Participants were asked "How would you rate the change in appearance of your lateral canthal lines (crow's feet) at maximum smile compared with immediately before the injection". Participants were then instructed to select on rating that best describes the degree to which the appearance of their lateral canthal lines at maximum smile has changed relative to baseline. The participant could review the baseline photographs to aid in the assessment. Responder rate is defined as percentage of participants who responds at least "Improved" (i.e., improved, much improved and very much improved) on the GAIS at maximum smile.

    Time frame: Month 1

07

Results

Posted May 29, 2026

Participant flow

This study was conducted at a single site in the United States of America from 23 January 2023 to 23 June 2023.

Participant flow — Overall Study
MilestoneQM1114-DP
Started25
Completed25
Not completed0

Outcome measures

PrimaryResponders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines)

The GAIS is a 7-point scale ranging from 1 to 7 where 1 = "very much improved", 2 = "much improved", 3 ="improved", 4 = "no change", 5 = "worse", 6 = "much worse" and 7 = "very much worse". Participants were asked "How would you rate the change in appearance of your glabellar lines (lines between your eyebrows) at maximum frown compared with immediately before the injection?". Participants were then instructed to select on rating that best describes the degree to which the appearance of their glabellar lines at maximum frown has changed relative to baseline. The participant could review the baseline photographs to aid in the assessment. Responder rate is defined as percentage of participants who responds at least "Improved" (i.e., improved, much improved and very much improved) on the GAIS at maximum frown.

Time frame:
Month 1
Reported as:
Number · percentage of participants
Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines)
percentage of participantsQM1114-DP
Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines)100 (86.28 to 100)
PrimaryResponders Rate Using the GAIS at Maximum Smile (Lateral Canthal Lines)

The GAIS is a 7-point scale ranging from 1 to 7 where 1 = "very much improved", 2 = "much improved", 3 ="improved", 4 = "no change", 5 = "worse", 6 = "much worse" and 7 = "very much worse". Participants were asked "How would you rate the change in appearance of your lateral canthal lines (crow's feet) at maximum smile compared with immediately before the injection". Participants were then instructed to select on rating that best describes the degree to which the appearance of their lateral canthal lines at maximum smile has changed relative to baseline. The participant could review the baseline photographs to aid in the assessment. Responder rate is defined as percentage of participants who responds at least "Improved" (i.e., improved, much improved and very much improved) on the GAIS at maximum smile.

Time frame:
Month 1
Reported as:
Number · percentage of participants
Responders Rate Using the GAIS at Maximum Smile (Lateral Canthal Lines)
percentage of participantsQM1114-DP
Responders Rate Using the GAIS at Maximum Smile (Lateral Canthal Lines)100 (86.28 to 100)

Adverse events

Collected over From Day 0 up to Month 4. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QM1114-DP0/25 (0%)0/25 (0%)2/25 (8%)
Most frequent other events
Most frequent other events
EventQM1114-DP
Injection site bruisingGeneral disorders2/25

Baseline characteristics

Analysis was performed on the safety set which included all participants who were injected in at least one of the glabellar lines or lateral canthal lines.

Age, Continuous
Age, Continuous(years)QM1114-DP
Mean45.5 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)QM1114-DP
Female21
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)QM1114-DP
Hispanic or Latino4
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QM1114-DP
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White23
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Galderma Research Site
    New York, New York 10021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2023, 2 months.

Results were first posted in May 2026, 3 years 1 month after primary completion. A results delay was requested in Mar 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2021
First posted
Dec 7, 2021
StartActual
Jan 23, 2023
Primary completionActual
Mar 31, 2023
CompletionActual
Jun 23, 2023
Results delay requested
Mar 25, 2024
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05148000
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Jan 23, 2023
Primary completion
Mar 31, 2023
Completion
Jun 23, 2023
Results posted
May 29, 2026
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion